Glitact (Pioglitazone)

Glitact is indicated for the treatment of type 2 diabetes mellitus as part of a comprehensive management plan.

• Used as monotherapy in patients who cannot tolerate metformin.
• Added to existing metformin therapy to improve glycemic control.
• Combined with other oral antidiabetic agents such as sulfonylureas or DPP‑4 inhibitors when additional glucose lowering is needed.
• May be considered in patients with insulin resistance where improving insulin sensitivity is a therapeutic goal.
• Prescribed alongside lifestyle interventions including diet modification and regular physical activity.

The safety profile of Glitact includes a range of adverse events that are reported with varying frequency.

Common

• Fluid retention that may present as mild peripheral edema, especially in the lower extremities.
• Gradual weight gain, often associated with increased fluid volume.
• Mild upper respiratory tract infections such as common cold symptoms.
• Headache of varying intensity, usually transient.
• Nausea or mild gastrointestinal discomfort, usually transient.

Serious

• Hepatotoxicity, indicated by significant elevations in liver transaminases (ALT/AST) and possible hepatitis.
• Exacerbation of congestive heart failure, characterized by worsening dyspnea, edema, and reduced exercise tolerance.
• Rare occurrences of bone fractures, particularly in patients with pre‑existing osteoporosis.
• Severe hypoglycemia when combined with insulin or sulfonylureas.

When prescribing Glitact, clinicians should evaluate several precautionary factors to ensure safe use.

• Assess liver function before initiation and monitor periodically during therapy.
• Use cautiously in patients with a history of heart failure or reduced ejection fraction.
• Evaluate renal function, as dose adjustment may be required in severe impairment.
• Consider the risk of bone loss in postmenopausal women or individuals with osteoporosis.
• Review concomitant medications that may increase fluid retention or affect glucose levels.
• Advise patients to report unexplained weight gain, swelling, or signs of liver injury promptly.

Glitact may interact with other medicines, influencing its efficacy or safety profile.

Avoid

• Concurrent use with potent CYP2C8 inhibitors (e.g., gemfibrozil) which can increase pioglitazone plasma concentrations.
• Combination with insulin or sulfonylureas without dose adjustment, due to heightened risk of hypoglycemia.
• Co‑administration with thiazide diuretics that may exacerbate fluid retention.

Use with caution

• Use with other thiazolidinediones is not recommended; additive effects on edema and heart failure risk.
• Concomitant use of NSAIDs may increase the likelihood of renal impairment.
• Combining with oral contraceptives may alter hormone levels; monitor for menstrual irregularities.
• When used with warfarin, monitor INR more frequently as pioglitazone may affect anticoagulant control.